10 Best AI Driven Biotech Stocks to Invest In

9. Kymera Therapeutics Inc. (NASDAQ:KYMR)

Kymera Therapeutics Inc. (NASDAQ:KYMR) is one of the 10 best AI driven biotech stocks to invest in.

On June 8, Brookline Capital Markets increased the target price for Kymera Therapeutics (NASDAQ:KYMR) from $91 to $97, resulting in a revised upside potential in excess of 30%. The firm also upheld its Buy rating on the stock amid the latest preclinical outcome related to KT-579. The data, presented at FOCUS and EULAR, exhibit similar or more enhanced activity relative to the approved clinical agents, and also show disease-altering characteristics across the lupus models.

Back in May, new preclinical findings for KT-579, a powerful and selective oral IRF5 degrader, were released by Kymera Therapeutics Inc. (NASDAQ:KYMR). The findings emphasized the drug’s potential to change inflammatory bowel disease (IBD). The results, which were demonstrated at Digestive Disease Week (DDW) 2026 in Chicago, show that targeted degradation of IRF5 can concurrently modulate multiple important inflammatory pathways that are involved in complex autoimmune diseases, such as pro-inflammatory cytokines, autoantibody responses, and Type I interferons.

Despite current treatments, numerous individuals with chronic inflammatory illnesses still have insufficient disease control, according to Kymera. KT-579 is designed to offer a convenient oral therapy capable of addressing multiple disease-driving mechanisms at once. Prior preclinical research in models of rheumatoid arthritis and lupus revealed activity that was either on par with or better than the existing standards of care.

KT-579 decreased the severity of the disease, stopped weight loss, preserved colon health, inhibited important inflammatory cytokines, and enhanced tissue pathology in an IBD TNBS model. Extensive normalization of inflammatory and fibrosis-related pathways was revealed by transcriptomic studies. Data from a Phase 1 healthy volunteer study evaluating KT-579 is anticipated in the latter half of 2026.

Kymera Therapeutics Inc. (NASDAQ:KYMR) is a biopharmaceutical company that discovers and develops small-molecule therapeutics to destroy the specific proteins that cause disease in the human body. It is developing KT-579, KT-485/SAR447971, cyclin-dependent kinase 2 (CDK2) and KT-621. The company is also working on the IRAK4 program, which is in Phase II clinical trial.